RESUMO
A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydronaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (24b), represents a 10- to 250-fold enhancement in AMPDA inhibitory potency without loss in the enzyme specificity. The potency of the inhibitor 24b (AMPDA K(i) = 0.002 microM) is 10(5)-fold lower than the Km for the substrate AMP. It represents the most potent nonnucleotide AMPDA inhibitor known.
Assuntos
AMP Desaminase/antagonistas & inibidores , Azepinas/síntese química , Inibidores Enzimáticos/síntese química , Imidazóis/síntese química , AMP Desaminase/química , Adenosina Desaminase/química , Inibidores de Adenosina Desaminase , Animais , Azepinas/química , Bovinos , Desenho de Fármacos , Inibidores Enzimáticos/química , Humanos , Imidazóis/química , Relação Estrutura-AtividadeRESUMO
Cell number is regulated by maintaining a balance between cell proliferation and cell death through apoptosis. Key regulators of this balance include the oncogene product c-Myc, which promotes either entry into the cell cycle or apoptosis [1]. Although the mechanism of c-Myc-induced apoptosis remains unclear, it is susceptible to regulation by survival factors [2,3] and can proceed through the interaction of Fas ligand (FasL) with its receptor, Fas [4]. Activated T lymphocytes are eliminated by an apoptotic process known as activation-induced cell death (AICD), which requires the transcriptional induction of FasL expression [5-7] and sustained levels of c-Myc [8]. The FasL promoter can be driven by c-Myc overexpression, and functional inhibitors of Myc and its binding partner, Max, inhibit the transcriptional activity of the FasL promoter [9,10]. We identified a non-canonical binding site (ATTCTCT) for c-Myc-Max heterodimers in the FasL promoter, which, when mutated, abolished activity in response to c-Myc. Exchange of the canonical c-Myc responsive elements (CACGTG) in the ornithine decarboxylase (ODC) promoter [11] with the non-canonical sequence in the FasL promoter generated an ODC-FasL promoter that was significantly more responsive to c-Myc than the wild-type ODC promoter. Our findings identify a precise physiological role for c-Myc in the induction of apoptosis as a transcriptional regulator of the FasL gene.
Assuntos
Proteínas de Ligação a DNA/metabolismo , Glicoproteínas de Membrana/genética , Regiões Promotoras Genéticas , Proteínas Proto-Oncogênicas c-myc/metabolismo , Sequência de Bases , Proteína Ligante FasRESUMO
N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1, 3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)ethyl]-3,6,7,8-tetrahydroimidazo[4, 5-d][1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K(i) = 0. 06 microM. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.
Assuntos
AMP Desaminase/antagonistas & inibidores , Azepinas/síntese química , Coformicina/análogos & derivados , Coformicina/síntese química , Inibidores Enzimáticos/síntese química , Imidazóis/síntese química , AMP Desaminase/química , Azepinas/química , Coformicina/química , Inibidores Enzimáticos/química , Imidazóis/química , Relação Estrutura-AtividadeRESUMO
A series of N3-substituted coformycin aglycon analogues are described that inhibit adenosine 5'-monophosphate deaminase (AMPDA) or adenosine deaminase (ADA). The key steps involved in the preparation of these compounds are (1) treating the sodium salt of 6, 7-dihydroimidazo[4,5-d][1,3]diazepin-8(3H)-one (4) with an alkyl bromide or an alkyl mesylate to generate the N3-alkylated compound 5 and (2) reducing 5 with NaBH(4). Selective inhibition of AMPDA was realized when the N3-substituent contained a carboxylic acid moiety. For example, compound 7b which has a hexanoic acid side chain inhibited AMPDA with a K(i) = 4.2 microM and ADA with a K(i) = 280 microM. Substitution of large lipophilic groups alpha to the carboxylate provided a moderate potency increase with maintained selectivity as exemplified by the alpha-benzyl analogue 7j (AMPDA K(i) = 0.41 microM and ADA K(i) > 1000 microM). These compounds, as well as others described in this series of papers, are the first compounds suitable for testing whether selective inhibition of AMPDA can protect tissue from ischemic damage by increasing local adenosine concentrations at the site of injury and/or by minimizing adenylate loss.
Assuntos
AMP Desaminase/antagonistas & inibidores , Coformicina/análogos & derivados , Coformicina/síntese química , Inibidores Enzimáticos/síntese química , AMP Desaminase/química , Animais , Bovinos , Membrana Celular/metabolismo , Células Cultivadas , Coformicina/química , Coformicina/metabolismo , Endotélio/citologia , Endotélio/metabolismo , Inibidores Enzimáticos/química , Inibidores Enzimáticos/metabolismo , Eritrócitos/metabolismo , Isquemia/prevenção & controle , Fígado/citologia , Espectroscopia de Ressonância Magnética , Coelhos , Ratos , Relação Estrutura-AtividadeRESUMO
AMP deaminase (AMPDA) inhibitors increase the levels of extracellular adenosine and preserve intracellular adenylate pools in cellular models of ATP depletion and therefore represent a potential new class of antiischemic drugs. Recently we reported that replacement of the ribose 5'-monophosphate component of the very potent transition-state analogue AMPDA inhibitor coformycin monophosphate (1) with a simple alkylcarboxy group resulted in potent, selective, and cell-penetrating AMPDA inhibitors. Here we report that replacement of this alkylcarboxy group with an alpha-substituted alkylmalonic acid resulted in enhanced inhibitor potency. The lead compound, 3-(5, 5-dicarboxy-6-(3-(trifluoromethyl)phenyl)-n-hexyl)coformycin aglycon (21), exhibited an AMPDA K(i) of 0.029 microM which is (3 x 10(5))-fold lower than the K(M) for the natural substrate AMP. A comparison of inhibitory potencies shows that the diacid analogues with alpha-benzyl substituents are 2-10-fold more inhibitory than similar monoacid-monoester, monoester-monoamide, or diester derivatives. Finally, these diacid analogues are 2-40-fold more potent inhibitors than the corresponding monocarboxylates.
Assuntos
AMP Desaminase/antagonistas & inibidores , Coformicina/análogos & derivados , Coformicina/síntese química , Inibidores Enzimáticos/síntese química , Malonatos/síntese química , Ribose/química , AMP Desaminase/química , Sítios de Ligação , Coformicina/química , Inibidores Enzimáticos/química , Malonatos/química , Mimetismo Molecular , Organofosfatos/química , Relação Estrutura-AtividadeRESUMO
Cell death due to thymine (dThd) deficiency, associated with the cytotoxic action of 5-fluorouracil in colon cancer, is regulated in thymidylate synthase-deficient (TS(-)) human colon carcinoma cells via the Fas (CD95, APO-1) death receptor. This was demonstrated by inhibiting the loss in clonogenicity of TS(-) cells by anti-FasL and in enhanced survival of TS(-) clones selected for resistance to Fas-mediated apoptosis, following dThd deprivation. During thymineless stress in TS(-) cells, Fas ligand (FasL) is expressed, and its promoter (hFasLPr) is activated. Transactivation of hFasLPr, dependent upon dThd deficiency, was inhibited following mutation of the binding sites for NF-kappaB or AP-1 and by preventing NF-kappaB or AP-1 activation, which inhibited expression of FasL and enhanced clonogenic survival in stable transformants expressing IkappaBalphaM or DN-MEKK, respectively. These results demonstrate the crucial roles for NF-kappaB and AP-1 in the regulation of FasL in Fas-mediated thymineless death of colon carcinoma cells.
Assuntos
Apoptose , Proteínas I-kappa B , Glicoproteínas de Membrana/metabolismo , NF-kappa B/metabolismo , Timina/metabolismo , Fator de Transcrição AP-1/metabolismo , Sobrevivência Celular , Células Clonais , Neoplasias do Colo , Proteínas de Ligação a DNA/metabolismo , Proteína Ligante Fas , Humanos , Glicoproteínas de Membrana/genética , Inibidor de NF-kappaB alfa , Regiões Promotoras Genéticas , Proteínas Recombinantes/metabolismo , Timidilato Sintase/deficiência , Ativação Transcricional , Transfecção , Células Tumorais CultivadasRESUMO
The transcription factor c-Myc is important for the control of cell cycle progression, neoplasia, and apoptotic cell death. c-Myc dimerizes with its partner Max to form an active transcription factor complex. Little is known, however, about the transcriptional targets of c-Myc and their roles in c-Myc-induced cell death. Here we demonstrate that T cell activation-induced expression of Fas ligand (FasL, CD95-L, APO-1-L), which can induce apoptotic cell death in many different cell types, is regulated by c-Myc. Down-modulation of c-Myc protein via antisense oligonucleotides blocked activation-induced FasL mRNA and protein expression and functional FasL expression in activated T cells and T cell lines. Further, FasL promoter activity in T cells is driven by overexpression of c-Myc and inhibited by expression of dominant-negative mutants of c-Myc and Max. Our findings indicate that c-Myc controls apoptotic cell death in T cells through regulation of FasL expression.
Assuntos
Regulação da Expressão Gênica/fisiologia , Glicoproteínas de Membrana/genética , Proteínas Proto-Oncogênicas c-myc/fisiologia , Linfócitos T/metabolismo , Sequência de Bases , Sítios de Ligação , Primers do DNA , Proteína Ligante Fas , Humanos , Regiões Promotoras Genéticas , Proteínas Proto-Oncogênicas c-myc/metabolismoRESUMO
Deletion of activated peripheral T cell clones by apoptosis requires the regulated expression of Fas ligand (FasL) and sensitization of these cells to CD95-mediated signaling. To investigate the signaling pathways responsible for FasL expression in T cells, we tested-besides subfamily-selective protein kinase C (PKC) inhibitors - the effect of constitutively active mutants of representatives of all PKC subfamilies, i.e. PKCalpha,epsilon,theta,iota, on FasL luciferase promoter reporter constructs. In synergy with a constitutively active form of protein phosphatase 2B calcineurin (CaN), only PKCtheta, but not PKCalpha,epsilon,iota, preferentially induced FasL promoter reporter activity and, consequently, FasL protein expression in Jurkat T cells. Activation of an inducible PKCtheta AE-estrogen receptor fusion mutant led to a CaN-dependent and rapid FasL reporter activity detected as early as 4 h after addition of 4-hydroxytamoxifen, incidating a direct effect of PKCtheta action on FasL expression. Consistently, in Jurkat T cells, expression of PKCtheta AE / CaN significantly enhanced FasL protein expression and apoptosis in a CD95-dependent manner since cell death was not observed in T cells co-expressing the caspase-8 inhibitor crmA. Taken together, our results support the notion that PKCtheta and CaN are sufficient to regulate apoptosis through FasL expression.
Assuntos
Apoptose , Calcineurina/metabolismo , Isoenzimas/metabolismo , MAP Quinase Quinase Quinase 1 , Glicoproteínas de Membrana/genética , Regiões Promotoras Genéticas , Proteína Quinase C/metabolismo , Proteínas Serina-Treonina Quinases , Serpinas/metabolismo , Proteínas Virais , Antígenos Transformantes de Poliomavirus/genética , Calcineurina/genética , Proteína Ligante Fas , Expressão Gênica , Humanos , Ionomicina/farmacologia , Isoenzimas/genética , Células Jurkat , Ligantes , MAP Quinase Quinase Quinases/metabolismo , Sistema de Sinalização das MAP Quinases , Glicoproteínas de Membrana/biossíntese , Mitógenos/farmacologia , NF-kappa B/metabolismo , Proteína Quinase C/genética , Proteína Quinase C-theta , Transdução de Sinais , Acetato de Tetradecanoilforbol/farmacologia , Fator de Transcrição AP-1/metabolismo , Transcrição Gênica , Ativação TranscricionalRESUMO
Activation-induced cell death is mediated by the TCR-induced expression of the Fas ligand (FasL) on the surface of T cells, followed by binding to its receptor Fas. FasL expression is induced by stimulating T cells with a combination of phorbol ester and Ca2+ ionophore, implicating a role for protein kinase C (PKC) in this process. However, the precise mechanisms that regulate FasL expression, including the contribution of distinct T cell-expressed PKC isoforms, are poorly understood. Herein, we report that PKCtheta, a Ca2+-independent PKC isoform that we have previously isolated as a PKC enzyme selectively expressed in T cells, plays an important role in these processes. A constitutively active PKCtheta mutant preferentially induced FasL expression and activated the corresponding gene promoter; conversely, a dominant-negative PKCtheta mutant blocked FasL expression induced by anti-CD3 or PMA plus ionomycin stimulation. Furthermore, PKCtheta synergized with calcineurin to provide a potent stimulus for FasL promoter activation. Full activation of the promoter required its binding sites for the transcription factors NF-AT, AP-1, and NF-kappaB. The biological significance of these findings is implicated by the finding that rottlerin, a selective PKCtheta inhibitor, blocked FasL induction by anti-CD3 or PMA plus ionomycin stimulation and, consequently, protected human Jurkat T cells and the mouse T cell hybridoma A1.1 from activation-induced cell death.
Assuntos
Apoptose/fisiologia , Calcineurina/metabolismo , Isoenzimas/metabolismo , Glicoproteínas de Membrana/genética , Proteínas Nucleares , Proteína Quinase C/metabolismo , Linfócitos T/imunologia , Acetofenonas/farmacologia , Animais , Benzopiranos/farmacologia , Sítios de Ligação , Carbazóis/farmacologia , Proteínas de Ligação a DNA/metabolismo , Interações Medicamentosas , Proteína Ligante Fas , Regulação da Expressão Gênica , Humanos , Indóis/farmacologia , Ionomicina/farmacologia , Isoenzimas/antagonistas & inibidores , Isoenzimas/genética , Células Jurkat , Glicoproteínas de Membrana/biossíntese , Camundongos , Mutação , Fatores de Transcrição NFATC , Regiões Promotoras Genéticas , Proteína Quinase C/antagonistas & inibidores , Proteína Quinase C/genética , Proteína Quinase C-theta , Transdução de Sinais , Acetato de Tetradecanoilforbol/farmacologia , Fator de Transcrição AP-1/metabolismo , Fatores de Transcrição/metabolismoRESUMO
POU domain proteins have been implicated as key regulators during development and lymphocyte activation. The POU domain protein T-cell factor beta1 (TCFbeta1), which binds octamer and octamer-related sequences, is a potent transactivator. In this study, we showed that TCFbeta1 is phosphorylated following activation via the T-cell receptor or by stress-induced signals. Phosphorylation of TCFbeta1 occurred predominantly at serine and threonine residues. Signals which upregulate Jun kinase (JNK)/stress-activated protein kinase activity also lead to association of JNK with TCFbeta1. JNK associates with the activation domain of TCFbeta1 and phosphorylates its DNA binding domain. The phosphorylation of recombinant TCFbeta1 by recombinant JNK enhances the ability of TCFbeta1 to bind to a consensus octamer motif. Consistent with this conclusion, TCFbeta1 upregulates reporter gene transcription in an activation- and JNK-dependent manner. In addition, inhibition of JNK activity by catalytically inactive MEKK (in which methionine was substituted for the lysine at position 432) also inhibits the ability of TCFbeta1 to drive inducible transcription from the interleukin-2 promoter. These results suggest that stress-induced signals and T-cell activation induce JNK, which then acts on multiple cis sequences by modulating distinct transactivators like c-Jun and TCFbeta1. This demonstrates a coupling between the JNK activation pathway and POU domain proteins and implicates TCFbeta1 as a physiological target in the JNK signal transduction pathway leading to coordinated biological responses.
Assuntos
Proteínas Quinases Dependentes de Cálcio-Calmodulina/metabolismo , Proteínas de Ligação a DNA/metabolismo , Proteínas Quinases Ativadas por Mitógeno , Proteínas Quinases/metabolismo , Sequência de Aminoácidos , Sítios de Ligação , DNA/metabolismo , Proteínas de Ligação a DNA/genética , Humanos , Interleucina-2/genética , Proteínas Quinases JNK Ativadas por Mitógeno , Células Jurkat , Proteína Quinase 9 Ativada por Mitógeno , Dados de Sequência Molecular , Fatores do Domínio POU , Fosforilação , Regiões Promotoras Genéticas , Proteínas Quinases/genética , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Ativação TranscricionalRESUMO
T cell receptor engagement activates transcription factors important for cytokine gene regulation. Additionally, this signaling pathway also leads to activation-induced apoptosis in T lymphocytes that is dependent on FasL transcription and expression. Here we demonstrate that nuclear factor kappaB (NF-kappaB), which is involved in the transcriptional regulation of many cytokine genes expressed in activated lymphocytes, also plays a role in T cell activation-induced FasL expression. Inhibition of NF-kappaB activity in a T cell hybridoma leads to decreased FasL expression and apoptosis upon T cell receptor stimulation. We identified the NF-kappaB site in the FasL promoter that contributes to such regulation. Co-expression of p65 (Rel A) with the FasL promoter enhanced its activity, and co-expression of IkappaB dramatically inhibited the inducible promoter activity. In contrast, the transcription factor AP-1 is not required for activation-induced FasL promoter activity. These results define a role for NF-kappaB in mediating FasL expression during T cell activation.
Assuntos
Morte Celular , Glicoproteínas de Membrana/metabolismo , NF-kappa B/metabolismo , Linfócitos T/metabolismo , Sequência de Bases , DNA , Proteína Ligante Fas , Humanos , Células Jurkat , Glicoproteínas de Membrana/genética , NF-kappa B/antagonistas & inibidores , Estresse Oxidativo , Regiões Promotoras Genéticas , Proteínas Proto-Oncogênicas c-jun/metabolismo , Receptores de Antígenos de Linfócitos T/metabolismoRESUMO
Activation-induced cell death (AICD) is a process that regulates the size and the duration of the primary immune T cell response. In this report, we investigated the mechanisms involved in the regulation of AICD by transforming growth factor beta1 (TGF-beta1). We found that TGF-beta1 decreased apoptosis of human T cells or T cell hybridomas after activation by anti-CD3. This decrease was associated with inhibition of Fas (Apo-1/CD95) ligand (FasL) expression, whereas Fas signaling was not affected by TGF-beta1. In parallel, TGF-beta1 inhibited c-Myc expression in T cell hybridomas, and ectopic expression of a chimeric molecule composed of c-Myc and the steroid binding domain of the estrogen receptor (Myc-ER) blocked both the inhibition of FasL and the decrease of AICD induced by TGF-beta1, providing that 4-hydroxytamoxifen was present. These results identify one mechanism by which TGF-beta1 blocks AICD to allow the clonal expansion of effector T cells and the generation of memory T cells during immune responses.
Assuntos
Apoptose/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-myc/genética , Linfócitos T/efeitos dos fármacos , Fator de Crescimento Transformador beta/farmacologia , Animais , Complexo CD3/imunologia , Ciclo Celular/efeitos dos fármacos , Fragmentação do DNA/efeitos dos fármacos , Fragmentação do DNA/genética , Proteína Ligante Fas , Regulação da Expressão Gênica/genética , Hibridomas/efeitos dos fármacos , Glicoproteínas de Membrana/genética , Camundongos , RNA Mensageiro/genética , Receptores de Estrogênio/genética , Proteínas Recombinantes de Fusão/genética , Tamoxifeno/análogos & derivados , Tamoxifeno/farmacologiaRESUMO
Apoptosis induced by DNA damage and other stresses can proceed via expression of Fas ligand (FasL) and ligation of its receptor, Fas (CD95). We report that activation of the two transcription factors NF-kappa B and AP-1 is crucially involved in FasL expression induced by etoposide, teniposide, and UV irradiation. A nondegradable mutant of I kappa B blocked both FasL expression and apoptosis induced by DNA damage but not Fas ligation. These stimuli also induced the stress-activated kinase pathway (SAPK/JNK), which was required for the maximal induction of apoptosis. A 1.2 kb FasL promoter responded to DNA damage, as well as coexpression with p65 Rel or Fos/Jun. Mutations in the relevant NF-kappa B and AP-1 binding sites eliminated these responses. Thus, activation of NF-kappa B and AP-1 contributes to stress-induced apoptosis via the expression of FasL.
Assuntos
Dano ao DNA/imunologia , Proteínas Quinases Ativadas por Mitógeno , NF-kappa B/metabolismo , Linfócitos T/citologia , Fator de Transcrição AP-1/metabolismo , Receptor fas/genética , Antígenos de Superfície/metabolismo , Apoptose/genética , Apoptose/imunologia , Proteínas Quinases Dependentes de Cálcio-Calmodulina/metabolismo , Proteína Ligante Fas , Regulação Enzimológica da Expressão Gênica/imunologia , Humanos , Proteínas Quinases JNK Ativadas por Mitógeno , Células Jurkat/química , Células Jurkat/citologia , Células Jurkat/enzimologia , Glicoproteínas de Membrana/metabolismo , Dados de Sequência Molecular , Regiões Promotoras Genéticas/imunologia , Transdução de Sinais/imunologia , Linfócitos T/química , Linfócitos T/enzimologiaRESUMO
Structure-activity studies have been performed to optimize the potency of this novel series of AMPDA inhibitors. Conformational rigidification of the N-3 sidechain resulted in substantial effect on the potency. Addition of the hydrophobic groups provided further benefit. The most potent compound identified, 4g (Ki = 3 nM), bears little structural resemblance to AMP and exhibits a remarkable improvement (10(3) and 10(5)) in binding affinity relative to the original lead and AMP, respectively. The application of prodrug strategy achieved a large improvement (benzyl ester 5d) in oral bioavailability, resulting in compounds that should be useful in evaluating the role of AMPDA in normo- and pathophysiological states.
Assuntos
AMP Desaminase/antagonistas & inibidores , Adenina/análogos & derivados , Adenina/química , Coformicina/análogos & derivados , Coformicina/química , Inibidores Enzimáticos/química , Adenina/síntese química , Adenina/farmacocinética , Monofosfato de Adenosina/química , Administração Oral , Disponibilidade Biológica , Coformicina/síntese química , Coformicina/farmacocinética , Desenho de Fármacos , Entropia , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacocinética , Humanos , Modelos Moleculares , Conformação Molecular , Estrutura Molecular , Relação Estrutura-AtividadeRESUMO
A major milestone in purine metabolism research has been achieved with the discovery of these potent and selective AMPDA inhibitors. These inhibitors of AMPDA are based on carboxypentyl substitution on N-3 of the coformycin aglycon. They are simpler than coformycin ribose 5'-monophosphate, more stable, selective against other AMP binding enzymes as well as ADA and have good cell penetration and good oral bioavailability. These compounds and their more potent analogs are the first compounds with suitable characteristics to allow a definitive analysis of the role of AMPDA in cellular metabolism and AMPDA as a therapeutic target.
Assuntos
AMP Desaminase/antagonistas & inibidores , Coformicina/análogos & derivados , Coformicina/química , Inibidores Enzimáticos/química , Administração Oral , Disponibilidade Biológica , Coformicina/síntese química , Coformicina/farmacocinética , Desenho de Fármacos , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacocinética , Humanos , Modelos Moleculares , Estrutura Molecular , Relação Estrutura-AtividadeRESUMO
T lymphocytes undergo apoptosis in response to cellular stress, including UV exposure and gamma irradiation. However, the mechanism by which stress stimuli induce apoptosis is not well understood. While stress stimuli induce the activation of the c-Jun N-terminal kinase (JNK) pathway, it is not clear whether the JNK cascade is activated as a result of cell death or whether the cascade participates in inducing apoptosis. Using a Jurkat T cell line transfected with dominant active (DA)-mitogen-activated protein kinase kinase kinase (MEKK1) in a tetracycline-regulated expression system, we found that expression of DA-MEKK1 results in the apoptosis of Jurkat cells in parallel with prolonged JNK activation. Moreover, DA-MEKK1 induced Fas ligand (FasL) cell surface and mRNA expression, as well as FasL promoter activation. Interference with Fas/FasL interaction prevented DA-MEKK1-mediated apoptosis. In comparing the effect of different stress stimuli to DA-MEKK1, we found that UV, gamma irradiation, and anisomycin prolonged JNK activation in parallel with FasL expression and onset of cell death. In addition, these stimuli also enhance cell surface expression of FasL. Interference with Fas/FasL interactions inhibited anisomycin but not UV- or gamma irradiation-induced apoptosis. Our data show that while the JNK pathway contributes to stress-induced apoptosis in T lymphocytes by regulating FasL expression, not all stress stimuli use the same cell death pathway.
Assuntos
Proteínas Quinases Dependentes de Cálcio-Calmodulina/fisiologia , Células Jurkat/citologia , MAP Quinase Quinase Quinase 1 , Glicoproteínas de Membrana/metabolismo , Proteínas Quinases Ativadas por Mitógeno , Proteínas Serina-Treonina Quinases/fisiologia , Proteínas Tirosina Quinases/fisiologia , Estresse Fisiológico/patologia , Apoptose , Antígenos CD28/fisiologia , Complexo CD3/fisiologia , Inibidores de Cisteína Proteinase/farmacologia , Proteína Ligante Fas , Regulação da Expressão Gênica , Humanos , Proteínas Quinases JNK Ativadas por Mitógeno , Glicoproteínas de Membrana/genética , Regiões Promotoras Genéticas , Transdução de Sinais , Receptor fas/fisiologiaRESUMO
Replication factor C (RF-C), a complex of five polypeptides, is essential for cell-free SV40 origin-dependent DNA replication and viability in yeast. The cDNA encoding the large subunit of human RF-C (RF-Cp145) was cloned in a Southwestern screen. Using deletion mutants of RF-Cp145 we have mapped the DNA binding domain of RF-Cp145 to amino acid residues 369-480. This domain is conserved among both prokaryotic DNA ligases and eukaryotic poly(ADP-ribose) polymerases and is absent in other subunits of RF-C. The PCNA binding domain maps to amino acid residues 481-728 and is conserved in all five subunits of RF-C. The PCNA binding domain of RF-Cp145 inhibits several functions of RF-C, such as: (i) in vitro DNA replication of SV40 origin-containing DNA; (ii) RF-C-dependent loading of PCNA onto DNA; and (iii) RF-C-dependent DNA elongation. The PCNA binding domain of RF-Cp145 localizes to the nucleus and inhibits DNA synthesis in transfected mammalian cells. In contrast, the DNA binding domain of RF-Cp145 does not inhibit DNA synthesis in vitro or in vivo. We therefore conclude that amino acid residues 481-728 of human RF-Cp145 are critical and act as a dominant negative mutant of RF-C function in DNA replication in vivo.
Assuntos
Replicação do DNA/fisiologia , Proteínas de Ligação a DNA/metabolismo , Proteínas de Homeodomínio , Antígeno Nuclear de Célula em Proliferação/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2 , Proteínas Repressoras , Proteínas de Saccharomyces cerevisiae , Sequência de Aminoácidos , DNA Complementar/genética , Proteínas de Ligação a DNA/química , Depressão Química , Humanos , Leucemia-Linfoma de Células T do Adulto/patologia , Substâncias Macromoleculares , Antígenos de Histocompatibilidade Menor , Dados de Sequência Molecular , Fragmentos de Peptídeos/metabolismo , Ligação Proteica , Conformação Proteica , Estrutura Terciária de Proteína , Proteínas Recombinantes de Fusão/metabolismo , Proteína de Replicação C , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Alinhamento de Sequência , Deleção de Sequência , Homologia de Sequência de Aminoácidos , Transfecção , Células Tumorais CultivadasRESUMO
The TCR is predicted to resemble the Fab fragment of an Ig molecule and by analogy to possess six Ag binding loops that contact MHC proteins bound with antigenic peptides. We have identified residues in the predicted Ag binding loops (beta 1, beta 2, and beta 3) on a TCR beta-chain that are important in the recognition of the MHC/antigenic peptide complex. Using site-directed mutagenesis, we altered the residues forming the predicted Ag binding site on the beta-chain expressed by the T lymphocyte clone D5, which specifically recognizes p-azobenzenearsonate-conjugated peptides presented by the class II MHC molecule I-Ad. Amino acid substitution of individual residues in each loop affected Ag recognition, demonstrating that all three putative Ag binding loops of the D5 TCR beta-chain are important in interaction with I-Ad/arsonate-conjugated Ag. Taken together with our previous work on the D5 TCR alpha-chain (Nalefski et al., J. Exp. Med. 175:1553), these results suggest that all six Ag binding loops of the D5 TCR alpha- and beta-chains interact simultaneously with the MHC/peptide complex. Consequently, the area of interaction between the TCR and the MHC/antigenic peptide complex is predicted to be extensive.
Assuntos
Antígenos de Histocompatibilidade Classe II/metabolismo , Receptores de Antígenos de Linfócitos T alfa-beta/química , Sequência de Aminoácidos , Animais , Arsenicais/imunologia , Sítios de Ligação , Complexo CD3/metabolismo , Células Clonais , Substâncias Macromoleculares , Camundongos , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Receptores de Antígenos de Linfócitos T alfa-beta/metabolismo , Relação Estrutura-Atividade , TransfecçãoRESUMO
Mutants of an untransformed T cell clone that no longer respond to TCR/CD3 stimulation have been derived using a selection procedure based on the loss of functional response to Ag. This functional selection gives rise to clones of several different phenotypes. We have previously described mutants with a TCR/CD3+ cell surface phenotype whose TCR are uncoupled from cellular responses. We describe six additional mutants that do not express TCR/CD3 at the cell surface. One of the CD3- clones contains a deletion in the successfully rearranged TCR-alpha gene, whereas another carries a deletion in the successfully rearranged TCR-beta gene. TCR/CD3 expression in these deletion mutants can be restored by transfection of TCR-alpha or TCR-beta DNA. Four other clones do not express TCR-beta mRNA, yet contain no obvious deletions or rearrangements in the TCR-beta genes. One of these clones does not transcribe TCR-beta chain mRNA. The mutation in this clone does not reside in the TCR-beta gene itself, but may instead reside in a trans-acting regulatory element affecting TCR-beta gene expression, because the TCR-beta mRNA-phenotype is complemented by fusion with a TCR-alpha-beta- cell line. TCR-beta chain regulatory mutants will be valuable in contributing to our understanding of how TCR expression is regulated.